scholarly journals Up-to-date knowledge of West Nile virus infection

2009 ◽  
Vol 62 (5-6) ◽  
pp. 231-235
Author(s):  
Ivana Hrnjakovic-Cvjetkovic ◽  
Dejan Cvjetkovic ◽  
Dusan Petric ◽  
Vesna Milosevic ◽  
Vera Jerant-Patic ◽  
...  

Virus West Nile virus is a single-stranded RNA virus of the family Flaviviridae, genus Flavivirus. Epidemiology West Nile virus is maintained in the cycle involving culicine mosquitoes and birds .Humans typically acquire West Nile infection through a bite from infected adult mosquito. Person to person transmission can occur through organ transplantation, blood and blood product transfusions, transplacentally and via brest milk. Human cases of West Nile infections were recorded in Africa, Israel, Russia, India, Pakistan. In Romania in 1996 West Nile fever occurred with hundreds of neurologic cases and 17 fatalities. First human cases in the United States were in New York City where 59 persons were infected and had fever, meningitis, encephalitis and flaccid paralysis. Clinical manifestation Most human cases are asymptomatic. The majority of symptomatic patients have a self limited febrile illness. Fatigue, nausea, vomiting, eye pain, headache, myalgias, artralgias, lymphadenopathy and rash are common complaints. Less than 1% of all infected persons develop more severe neurologic illness including meningitis, encefalitis and flaccid paralysis. Laboratory diagnosis Diagnosis of West Nile virus infection is based on serologic testing, isolation of virus from patient samples and detection of viral antigen or viral genom. ELISA test and indirect immunofluorescenceassay are used for detecting IgM and IgG antibodies in serum and cerebrospinal fluid. Treatment In vitro studies have suggested that ribavirin and interferon alfa -2b may be useful in the treatment of West Nile virus disease. Prevention The most important measures are mosquito control program and personal protective measures. .

2005 ◽  
Vol 51 (2) ◽  
pp. 120-127 ◽  
Author(s):  
M SAAD ◽  
S YOUSSEF ◽  
D KIRSCHKE ◽  
M SHUBAIR ◽  
D HADDADIN ◽  
...  

2005 ◽  
Vol 79 (23) ◽  
pp. 14606-14613 ◽  
Author(s):  
L. Hannah Gould ◽  
Jianhua Sui ◽  
Harald Foellmer ◽  
Theodore Oliphant ◽  
Tian Wang ◽  
...  

ABSTRACT West Nile virus has spread rapidly across the United States, and there is currently no approved human vaccine or therapy to prevent or treat disease. Passive immunization with antibodies against the envelope protein represents a promising means to provide short-term prophylaxis and treatment for West Nile virus infection. In this study, we identified a panel of 11 unique human single-chain variable region antibody fragments (scFvs) that bind the envelope protein of West Nile virus. Selected scFvs were converted to Fc fusion proteins (scFv-Fcs) and were tested in mice for their ability to prevent lethal West Nile virus infection. Five of these scFv-Fcs, 11, 15, 71, 85, and 95, protected 100% of mice from death when given prior to infection with virus. Two of them, 11 and 15, protected 80% of mice when given at days 1 and 4 after infection. In addition, four of the scFv-Fcs cross-neutralized dengue virus, serotype 2. Binding assays using yeast surface display demonstrated that all of our scFvs bind to sites within domains I and II of West Nile virus envelope protein. These recombinant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus infections.


2003 ◽  
Vol 9 (7) ◽  
pp. 788-793 ◽  
Author(s):  
James J. Sejvar ◽  
A. Arturo Leis ◽  
Dobrivoje S. Stokic ◽  
Jay A. Van Gerpen ◽  
Anthony A. Marfin ◽  
...  

2013 ◽  
Vol 32 (9) ◽  
pp. 1023-1024 ◽  
Author(s):  
Alexandra Soldatou ◽  
George Vartzelis ◽  
Stella Vorre ◽  
Anna Papa ◽  
Konstantinos Voudris ◽  
...  

2005 ◽  
Vol 54 (3) ◽  
pp. 159-160 ◽  
Author(s):  
Mahbouba Frih-Ayed ◽  
Amel Boughammoura-Bouatay ◽  
Foued Ben Romdhane ◽  
Saber Chebel ◽  
Mohamed Chakroun ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document